



## **CRISPR Therapeutics to Participate in Upcoming Investor Conferences**

**ZUG, Switzerland and CAMBRIDGE, Mass. – July 30, 2020** -- (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in August:

### **William Blair Biotech Focus Conference**

Date: Thursday, August 6, 2020

Panel: 1:00 p.m. ET

### **Canaccord Genuity 40th Annual Growth Conference**

Date: Thursday, August 13, 2020

Fireside chat: 2:30 p.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at <https://crisprtx.gcs-web.com/events>. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

### **About CRISPR Therapeutics**

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit [www.crisprtx.com](http://www.crisprtx.com).

### **Investor Contact:**

Susan Kim

+1-617-307-7503

[susan.kim@crisprtx.com](mailto:susan.kim@crisprtx.com)

### **Media Contact:**

Rachel Eides

WCG on behalf of CRISPR

+1-617-337-4167

[reides@wcgworld.com](mailto:reides@wcgworld.com)

###